Ignite Creation Date:
2024-05-06 @ 7:47 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06132438
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-15
First Post:
2023-11-02
Brief Title:
Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma
Sponsor:
Charlotte Lemech
Organization:
The University of New South Wales
Study Overview
Official Title:
Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma INTERROGATE-GBM
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In Australia glioblastoma GBM has a higher annual fatality rate than a variety of other cancers such as melanoma bladder and kidney tumors While the 5-year survival rate for other cancers such as breast and prostate cancer has increased there have been no notable advancements in GBM during the past ten years and the incidence and mortality patterns have barely changed between 1982 and 2011 In particular GBM poses a challenging therapeutic dilemma for patients and physicians due to its aggressive biology and resistance to available treatments Recent studies showed that cytomegalovirus CMV is expressed in GBM tumors making it a good target for immunotherapy trials This phase I trial aims to determine the safety and tolerability of the PEP-CMV vaccine in patients with newly diagnosed MGMT-unmethylated GBM in combination with one cycle of adjuvant temozolomide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None